GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LivaNova PLC (NAS:LIVN) » Definitions » Cyclically Adjusted PS Ratio

LivaNova (LivaNova) Cyclically Adjusted PS Ratio : 2.49 (As of Apr. 27, 2024)


View and export this data going back to 1993. Start your Free Trial

What is LivaNova Cyclically Adjusted PS Ratio?

As of today (2024-04-27), LivaNova's current share price is $55.53. LivaNova's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $22.31. LivaNova's Cyclically Adjusted PS Ratio for today is 2.49.

The historical rank and industry rank for LivaNova's Cyclically Adjusted PS Ratio or its related term are showing as below:

LIVN' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.99   Med: 5.66   Max: 10.38
Current: 2.47

During the past years, LivaNova's highest Cyclically Adjusted PS Ratio was 10.38. The lowest was 1.99. And the median was 5.66.

LIVN's Cyclically Adjusted PS Ratio is ranked worse than
52.9% of 465 companies
in the Medical Devices & Instruments industry
Industry Median: 2.11 vs LIVN: 2.47

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

LivaNova's adjusted revenue per share data for the three months ended in Dec. 2023 was $5.688. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $22.31 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


LivaNova Cyclically Adjusted PS Ratio Historical Data

The historical data trend for LivaNova's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LivaNova Cyclically Adjusted PS Ratio Chart

LivaNova Annual Data
Trend Apr14 Apr15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.08 4.10 4.82 2.69 2.32

LivaNova Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.69 2.06 2.36 2.39 2.32

Competitive Comparison of LivaNova's Cyclically Adjusted PS Ratio

For the Medical Devices subindustry, LivaNova's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LivaNova's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, LivaNova's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where LivaNova's Cyclically Adjusted PS Ratio falls into.



LivaNova Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

LivaNova's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=55.53/22.31
=2.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LivaNova's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, LivaNova's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=5.688/130.0000*130.0000
=5.688

Current CPI (Dec. 2023) = 130.0000.

LivaNova Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201401 2.500 98.700 3.293
201404 2.756 99.600 3.597
201407 2.675 99.600 3.491
201410 2.740 100.100 3.558
201501 2.722 99.200 3.567
201504 2.817 99.900 3.666
201507 3.089 100.000 4.016
201510 2.594 100.300 3.362
201603 5.866 100.400 7.595
201606 6.530 101.000 8.405
201609 6.017 101.500 7.707
201612 1.256 102.200 1.598
201703 4.708 102.700 5.959
201706 5.297 103.500 6.653
201709 5.177 104.300 6.453
201712 5.682 105.000 7.035
201803 5.091 105.100 6.297
201806 5.827 105.900 7.153
201809 5.594 106.600 6.822
201812 6.119 107.100 7.427
201903 5.198 107.000 6.315
201906 5.734 107.900 6.908
201909 5.502 108.400 6.598
201912 5.941 108.500 7.118
202003 4.970 108.600 5.949
202006 3.748 108.800 4.478
202009 4.935 109.200 5.875
202012 5.544 109.400 6.588
202103 5.080 109.700 6.020
202106 5.406 111.400 6.309
202109 4.909 112.400 5.678
202112 5.068 114.700 5.744
202203 4.433 116.500 4.947
202206 4.700 120.500 5.071
202209 4.719 122.300 5.016
202212 5.141 125.300 5.334
202303 4.887 126.800 5.010
202306 5.445 129.400 5.470
202309 5.299 130.100 5.295
202312 5.688 130.000 5.688

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


LivaNova  (NAS:LIVN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


LivaNova Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of LivaNova's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


LivaNova (LivaNova) Business Description

Traded in Other Exchanges
Address
20 Eastbourne Terrace, London, GBR, W2 6LG
U.K.-based LivaNova was born of a combination between Cyberonics in the U.S. and Sorin in Italy. The medical device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. LivaNova derives roughly half of its revenue from the U.S. market, another 21% from Europe, and the remainder from the rest of the world.
Executives
James Christopher Barry director 7475 LUSK BLVD, SAN DIEGO CA 92121
Damien Mcdonald officer: COO 5 MERCHANT SQUARE, NORTH WHARF ROAD, LONDON X0 W21AY
Michael Damon Hutchinson officer: Chief Legal Officer 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Brooke Story director C/O SIGILON THERAPEUTICS, INC., 100 BINNEY STREET, SUITE 600, CAMBRIDGE MA 02142
Peter M Wilver director
Daniel Jeffrey Moore director 100 CYBERONICS BVLD, HOUSTON TX 77058
Alfred J Novak director 325 NE 6TH ST, BOCA RATON FL 33432
William A Kozy director C/O BECTON DICKERSON & CO, 1 BECTON DR, FRANKLIN LAKES NJ 07417
Marco Dolci officer: SVP Global Operations, R&D VIA BENIGNO CRESPI 17, MILAN L6 20159
Todd C Schermerhorn director C/O C.R BARD INC, 730 CENTRAL AVE, MURRAY HILL NJ 07974
Alex Shvartsburg officer: Interim CFO 20 EASTBOURNE TERRACE, LONDON X0 W26LG
Roy Khoury officer: President, International 5 MERCHANT SQUARE, NORTH WHARF ROAD, LONDON X0 W21AY
Thad Allen Huston officer: Chief Financial Officer 941 BLOOMFIELD ST, HOBOKEN NJ 07030
Seng Stacy Enxing director C/O HILL-ROM HOLDINGS, INC., SUITE 4100 180 NORTH STETSON AVENUE, CHICAGO IL 60601
Trui Hebbelinck officer: Chief Human Resources Officer 20 EASTBOURNE TERRACE, LONDON X0 W2 6LG